547 related articles for article (PubMed ID: 23451806)
21. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
23. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Hanauer SB; Sandborn WJ; Kornbluth A; Katz S; Safdi M; Woogen S; Regalli G; Yeh C; Smith-Hall N; Ajayi F
Am J Gastroenterol; 2005 Nov; 100(11):2478-85. PubMed ID: 16279903
[TBL] [Abstract][Full Text] [Related]
24. Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Sandborn WJ; Hanauer S; Lichtenstein GR; Safdi M; Edeline M; Scott Harris M
Aliment Pharmacol Ther; 2011 Oct; 34(7):747-56. PubMed ID: 21848857
[TBL] [Abstract][Full Text] [Related]
25. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Connolly MP; Kuyvenhoven JP; Postma MJ; Nielsen SK
J Crohns Colitis; 2014 May; 8(5):357-62. PubMed ID: 24094599
[TBL] [Abstract][Full Text] [Related]
26. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
Farup PG; Hinterleitner TA; Lukás M; Hébuterne X; Rachmilewitz D; Campieri M; Meier R; Keller R; Rathbone B; Oddsson E
Inflamm Bowel Dis; 2001 Aug; 7(3):237-42. PubMed ID: 11515850
[TBL] [Abstract][Full Text] [Related]
27. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
[TBL] [Abstract][Full Text] [Related]
28. Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.
Tong JL; Huang ML; Xu XT; Qiao YQ; Ran ZH
J Dig Dis; 2012 Apr; 13(4):200-7. PubMed ID: 22435504
[TBL] [Abstract][Full Text] [Related]
29. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
Marakhouski Y; Fixa B; Holomán J; Hulek P; Lukas M; Bátovský M; Rumyantsev VG; Grigoryeva G; Stolte M; Vieth M; Greinwald R;
Aliment Pharmacol Ther; 2005 Jan; 21(2):133-40. PubMed ID: 15679762
[TBL] [Abstract][Full Text] [Related]
30. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Raedler A; Behrens C; Bias P
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1353-63. PubMed ID: 15606398
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
[TBL] [Abstract][Full Text] [Related]
32. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
[TBL] [Abstract][Full Text] [Related]
33. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.
Nishikawa AM; Paladini L; Delfini R; Kotze PG; Clark O
Arq Gastroenterol; 2013; 50(4):297-303. PubMed ID: 24474233
[TBL] [Abstract][Full Text] [Related]
34. Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
Hartmann F; Stein J;
Aliment Pharmacol Ther; 2010 Aug; 32(3):368-76. PubMed ID: 20491741
[TBL] [Abstract][Full Text] [Related]
35. Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Eliakim R; Tulassay Z; Kupcinskas L; Adamonis K; Pokrotnieks J; Bar-Meir S; Lavy A; Mueller R; Greinwald R; Chermesh I; Gross V;
Aliment Pharmacol Ther; 2007 Nov; 26(9):1237-49. PubMed ID: 17944738
[TBL] [Abstract][Full Text] [Related]
36. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Richter JM; Kushkuley S; Barrett JA; Oster G
Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748
[TBL] [Abstract][Full Text] [Related]
37. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.
Hiwatashi N; Suzuki Y; Mitsuyama K; Munakata A; Hibi T
J Gastroenterol; 2011 Jan; 46(1):46-56. PubMed ID: 20878425
[TBL] [Abstract][Full Text] [Related]
38. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB
Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
[TBL] [Abstract][Full Text] [Related]
39. Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
Biancone L; Gionchetti P; Blanco Gdel V; Orlando A; Annese V; Papi C; Sostegni R; D'Incà R; Petruzziello C; Casa A; Sica G; Calabrese E; Campieri M; Pallone F
Dig Liver Dis; 2007 Apr; 39(4):329-37. PubMed ID: 17347061
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Zheng X; Zhang Z; Wang B; Li J; Qiu C; Zhang Q; Wang X
Medicine (Baltimore); 2019 Apr; 98(14):e15113. PubMed ID: 30946380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]